BioWorld

April 11, 2007

Erbitux Misses In Pancreatic Cancer, Dropping ImClone

Shares in ImClone Systems Inc. took a 6.4 percent dip on word that Erbitux (cetuximab) missed the primary endpoint in a Phase III pancreatic cancer study, a backslide that follows a month of significant gains. (BioWorld Today) Read More

Ascenta Raises $50M For Apoptosis Phase II Trials

Entereg Data Show Heart Risks, Adolor Plummets

Inhibitex Acquiring FermaVir In All-Stock Deal Valued At $19M

Biosite To Consider IMI's Offer Over Rival Beckman

Advancis Raising $24M To Get Amoxicillin Pulsys To Market

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

Roche identifies new TREM2 agonists

BioWorld Science

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...

Plasticity, properly parsed, provides psychiatric platform

BioWorld

If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...